Zealand Pharma A/S

Zealand Pharma is a Danish biotech company that develops peptide-based medicines for metabolic diseases like diabetes and obesity. The company was founded in 1998 with a focus on designing drugs to be brought to market through partnerships with other pharmaceutical companies.

In 2010, Zealand Pharma went public on the Copenhagen Stock Exchange. Notable partnerships include the development of the diabetes medication Lyxumia in collaboration with Sanofi and the development of the medication Danegaptid in partnership with the coronary care unit at Rigshospitalet in Copenhagen. The company also develops orphan drugs with government assistance.

In 2019, the Dutch family foundation Van Herk Investments invested 560 million Danish Kroner in Zealand Pharma. In the same year, the company acquired Canadian biotech company Encycle Therapeutics, giving them the right to develop and sell the pre-clinical candidate medication ET3764, which is being developed for the treatment of diseases of the alimentary tract.

Dr. Adam Steensberg assumed the position of CEO in March 2022. The company does not sell products in the market itself but instead forms partnerships with pharmaceutical companies that are responsible for placing the products on the market.

Founded: 1998

Headquarters: Sydmarken 11, 2860 Søborg, Denmark

Website: https://www.zealandpharma.com/